Sana Biotechnology, Inc.
SANA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001770121
No open-market purchases or sales by Sana Biotechnology, Inc. insiders were filed in the last 90 days; 211 institutions reported holding it in 13F filings for Q2 2026, worth $644.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $686.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +11 vs. previous quarter
- 211
- 13F valueReported value at the end of Q2 2026
- $644.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$244.2M
- No comparable prior period
- Free cash flow, FY2025
- -$144.8M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 40.6M
- Shares sold short
- Change
- −246.6K
- −0.6% vs. previous
- Days to cover
- 15.77
- At average daily volume
Superinvestors holding SANA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding SANA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Sana Biotechnology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2025 (view filing) | Jan 8 | 2 days | FMR LLC10% Owner, Other: See Remark 1 | SSale | −290.9K | $6.49 | −$1.89M | −6.0%4.54M after | 4 lots |
| Sep 26, 2024 (view filing) | Sep 24-25 | 2 days | Mulligan RichardDirector | SSale | −300.0K | $3.99 | −$1.20M | −10.0%2.70M after | 2 lots10b5-1 |
| Mar 11, 2024 (view filing) | Mar 8 | 3 days | Yang Patrick YDirector | SSale | −25.0K | $9.45 | −$236.3K | −14.3%149.3K after | |
| Feb 14, 2024 (view filing)4:00 PM ET | Feb 12 | 2 days | Afeyan Noubar and 1 other10% Owner | PPurchase | +2.73M | $5.50 | +$15.0M | –2.73M after | Derivative |
| Feb 12, 2024 (view filing)5:43 PM ET | Feb 8 | 4 days | Crandell Keith and 3 others10% Owner | PPurchase | +1.82M | $5.50 | +$10.0M | +17.1%12.4M after | 3 lotsDuplicate filing |
| Feb 12, 2024 (view filing)5:43 PM ET | Feb 8 | 4 days | ARCH Venture Fund IX, L.P. and 9 others10% Owner | PPurchase | +1.82M | $5.50 | +$10.0M | +17.1%12.4M after | 3 lotsDuplicate filing |
| Feb 12, 2024 (view filing) | Feb 8 | 4 days | Nelsen RobertDirector, 10% Owner | PPurchase | +1.82M | $5.50 | +$10.0M | +17.1%12.4M after | 3 lots |
| Dec 18, 2023 (view filing) | Dec 15 | 3 days | Hordo ChristianEVP, Chief Business Officer | SSale | −75.0K | $4.00 | −$300.0K | −8.0%867.5K after | 10b5-1 |
| Jun 8, 2023 (view filing)7:00 PM ET | Jun 6-7 | 2 days | Afeyan Noubar and 3 others10% Owner | SSale | −403.8K | $6.27 | −$2.53M | −22.6%1.38M after | 4 lots |
| May 26, 2023 (view filing)8:00 PM ET | May 24-26 | 2 days | Afeyan Noubar and 3 others10% Owner | SSale | −545.2K | $6.47 | −$3.53M | −27.7%1.43M after | 6 lots |
Top 10 13F holders, Q2 2026
See all 211 holdersThe largest institutional positions in Sana Biotechnology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 37,429,515 | $130.6M | 0.01% | −7690.0% | Reduced |
| Flagship Pioneering Inc. | 25,001,856 | $87.3M | 5.67% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 18,750,000 | $65.4M | 0.57% | +18,750,000 | New |
| BlackRock, Inc. | 16,675,173 | $58.2M | 0.00% | +2,434,998+17.1% | Added |
| State Street Corp | 11,203,134 | $39.1M | 0.00% | +665,048+6.3% | Added |
| Canada Pension Plan Investment Board | 10,218,400 | $35.7M | 0.02% | −3,5000.0% | Reduced |
| Vanguard Capital Management LLC | 8,375,421 | $29.2M | 0.00% | +940,697+12.7% | Added |
| Bank of America Corp | 5,748,454 | $20.1M | 0.00% | +2,801,593+95.1% | Added |
| Geode Capital Management, LLC | 4,677,959 | $16.3M | 0.00% | +495,986+11.9% | Added |
| Marex Group plc | 3,989,100 | $13.9M | 0.10% | −10,000−0.3% | Reduced |
Holders of 5% or more of SANA
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Sana Biotechnology, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13G/A | 15.40%46.2M shares | −1.90 ppfrom 17.30% | Feb 10, 20226 filings | Aug 14, 2026 | SEC |
| FMR LLC | 13G/A | 12.50%37.3M shares | – | Feb 10, 20219 filings | Nov 5, 2026 | SEC |
| Ra Capital Management, L.P. | 13G | 6.30%18.8M shares | New | May 21, 20261 filing | May 21, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.10%13.6M shares | +0.20 ppfrom 4.90% | Oct 22, 20244 filings | Jan 21, 2026 | SEC |